Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Issued (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Shares Issued for 15 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued changed N/A year-over-year to $46.8 million, compared with a TTM value of $71.8 million through Dec 2025, up 3285.11%, and an annual FY2025 reading of $25.0 million, up 946.46% over the prior year.
  • Shares Issued was $46.8 million for Q4 2025 at Arrowhead Pharmaceuticals, up from -$216.4 million in the prior quarter.
  • Across five years, Shares Issued topped out at $216.4 million in Q2 2025 and bottomed at -$216.4 million in Q3 2025.
  • Average Shares Issued over 5 years is $4.4 million, with a median of $855000.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 55814.21% in 2025, while the deepest fall reached 97134.98% in 2025.
  • Year by year, Shares Issued stood at $1.9 million in 2021, then plummeted by 69.44% to $576000.0 in 2022, then plummeted by 53.65% to $267000.0 in 2023, then fell by 16.48% to $223000.0 in 2024, then surged by 20900.9% to $46.8 million in 2025.
  • Business Quant data shows Shares Issued for ARWR at $46.8 million in Q4 2025, -$216.4 million in Q3 2025, and $216.4 million in Q2 2025.